Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO906 in Advanced Melanoma
NCT00035165Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2002
- Primary completion
- May 2003
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patupilone in melanoma, sponsored by Novartis. Started Mar 2002; status: completed.
02
Drugs
patupilone
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00035165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035165.